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Abstract  
BACKGROUND: Lentigo malignant melanoma is a melanoma subtype of chronic sun-damaged skin in elderly 
Caucasians. Amelanotic variants of lentigo malignant are extremely rare. 
CASE PRESENTATION: This is a case report of an 80-year-old male patient who presented with a non-
pigmented exophytic tumour of his bald head. After complete surgical excision under the suspicion of squamous 
cell carcinoma, three-dimensional histologic examination confirmed an amelanotic lentigo malignant melanoma 
with a tumour thickness of 1.76 mm, resected R0. Five years later he developed the first relapse, the other year a 
satellite metastasis was surgically removed. One year later, this patient had developed a large relapsing lentigo 
malignant melanoma with skull roof invasion. There was no evidence of distant metastatic spread. Amelanotic 
lentigo malignant melanoma is a very rare tumour.  
CONCLUSIONS: Serial excision or slow Mohs and Mohs micrographic surgery are the treatments of choice 
especially in the head and neck area. These tumours may be locally very aggressive as it is shown by skull 
invasion in the present case. 
 
 
 
Introduction 
 
Lentigo malignant melanoma (LMM) is a 
melanoma subtype that develops on chronic sun-
damaged skin mostly in elderly patients (age >70 
years). Its precursor, lentigo maligna or Hutchinson’s 
melanotic freckle is a melanoma in situ on average 
with a remarkable slow growth rate. In 2% to 20% of 
patients lentigo maligna will further progress to 
invasive melanoma. Lentigo maligna and LMM may 
have similar clinical presentation, what challenges 
their differential diagnosis [1]. 
LMM accounts for 4% to 15% of all 
melanomas. The propensity to lentigines is higher in 
LMM versus superficial spreading melanoma (SSM), 
while high nevus counts are a stronger indicator for 
SSM. In addition, SSM is stronger associated to non-
melanoma skin cancer compared to SSM. Sunburns 
don’t seem to be not an independent risk factor for 
LMM [2]. A recent study from the Netherlands 
analysed age-standardized incidence rate for LMM 
between 1989 to 2013. The incidence rate increased 
from 0.24 to 1.19 [3]. 
On histopathologic examination LMM is 
characterised by the atypical junctional growth of 
melanocytic cells, pagetoid growth not only in 
interfollicular but follicular skin, cellular atypia, and 
increased proliferative activity. The affected skin 
shows marked epidermal atrophy, solar elastosis and 
dermal inflammatory infiltrate. LMM radial growth may 
regress, a feature that may notoriously lead to false 
negative surgical margins. Therefore, diagnosis of 
LMM is not an easy one especially in the 
interpretation of resection margins. To assist LMM 
diagnosis, various immunostains are used with 
monoclonal antibodies against S100, HMB-45 
(against Pmel 17), soluble adenylyl cyclase (antibody 
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R21), microphthalmia transcription factor or MART-1 
(protein melan-A) [1, 4]. 
Dermoscopy may aid melanoma diagnosis, 
but studies so far have considered pigmented LMM 
only [5, 6]. Confocal microscopy could be a tool for the 
definition of tumour margins before surgery, but the 
technique is yet no standard procedure [7]. 
 
 
Case report 
 
A 73-year-old male patient presented with a 
firm tumour on his bald head with a diameter of 
approximately 2 cm. The reason for the first 
presentation was frequent bleeding. 
He had a medical history of prostate cancer 
(Gleason score 7) and subsequent radiotherapy, 
squamous cell cancer of the right hand, arterial 
hypertension, hyperlipidemia, chronic ischemic heart 
disease with four by-passes and pace maker 
implantation. 
 
Figure 1: Amelanotic lentigo malignant melanoma of the bald head. 
(a) Initial presentation of the primary tumour resembling squamous 
cell carcinoma; (b) Relapse on the borders of the transplant, 
telangiectasias but again no pigmentation at all; (c) Surgical 
specimen; (d) Defect before closure with skull roof invasion located 
centrally 
 
 
On examination, we observed a skin coloured 
exophytic nodule, covered by scales (Fig. 1a). Under 
the working diagnosis of a squamous cell carcinoma, 
the tumour was removed by standard excision 
followed by three-dimensional histology. 
Histologic examination confirmed a lentigo 
malignant melanoma (LMM) with a tumour thickness 
of 1.76 mm and Clark level IV. The tumour cells were 
positive for S100 with coexpression of MART-1 and 
HMB45. They were negative for CD10 and CD68. 
The surgical margins were free. The staging 
was performed by imaging techniques. No metastases 
were observed. This lead to the final diagnosis of 
LMM (pT2b N0 M0). Healing was unremarkable. 
 
Figure 2: Histopathology of lentigo malignant melanoma. (a) 
Overview (hematoxylin-eosin x 2); (b) detail (hematoxylin-eosin x 4); 
(c) immunoperoxidase staining for S100 (x4) 
 
 
Five years later, he presented with an 
amelanotic relapse of his LMM, which was surgically 
removed by slow Mohs again. Tumour thickness was 
3.00 mm (rpT3a). Tumour staging was unremarkable, 
no metastases. 
One year later, he returned with another skin 
coloured nodule of the bald head which was removed 
by slow Mohs surgery. The defect was closed by 
sandwich transplantation using dermal equivalent 
(Matriderm) and meshed skin graft [8]. Histologic 
examination revealed a satellite metastasis of his 
LMM. Healing was uneventful. The tumour was now 
staged as rpT3a pN2c cM0, stage IIIb. 
 
Figure 3: Skull defect in magnetic resonance imaging 
 
 
Almost exactly one year later, he presented 
with a firm tumour proliferation around the skin 
transplant with some telangiectasias but without 
pigmentation (Fig. 1b). A skin biopsy was taken. 
Histologically, there was a proliferation of atypical 
melanocytes singly and in nests along the basal layer 
of the epidermis and epitheloid nests in the adjacent 
dermis. The atypical cells were small with prominent 
nuclei. These findings confirmed LMM (Fig. 2). 
Staging demonstrated a tabula externa defect (Fig. 3). 
Surgery was planned a tumour debulking. The patient 
was treated surgically as a tumour by wide excision 
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with 2 cm safety margins (Fig. 1c), after decortication 
the tabula externa was partially removed by a 
diamond drill. During surgery, it became obvious that 
the tumour had already infiltrated the skull roof in an 
area of about 4 x 2.5 cm (Fig. 1d). The defect was 
closed by sandwich transplantation (Fig. 4) and the 
patient was presented to the tumour board for either 
neurosurgery and radiotherapy. Since the tabula 
interna was still intact as demonstrated by cranial 
computerised tomography, he was referred to the 
neurosurgery and plastic surgery department for 
tumour removal and skull repair. Staging did not 
provide any hint for the further metastatic spread. 
 
 
Discussion 
 
In our department, LMM is seen in 12% of 
female and 11% of male melanoma patients. 
Amelanotic melanoma comprises only two percent of 
all melanoma subtypes. Amelanotic LMM is an 
unusual rare tumour type with less than 25 cases 
reported worldwide (9-15). The clinical suspicion for 
amelanotic LMM is extremely low. Dermoscopy is not 
sensitive enough to detect this melanoma subtype [5, 
6]. 
 
Figure 4: Four weeks after sandwich transplantation with a stable 
graft 
 
 
Major differential diagnoses are actinic 
keratosis and squamous cell carcinoma (SCC). 
Diagnosis can only be confirmed by histopathological 
examination. 
Due to the growth characteristics of LMM with 
recurrent regression, the assessment of free surgical 
margins is not an easy task. The medical history of 
our patient demonstrated that even with slow Mohs, 
experienced dermatopathologist and dermasurgeon, 
recurrence is possible [5]. 
The present case is exceptional for several 
reasons: (i) it is an amelanotic LMM; (ii) recurrence 
was only locally; (iii) it invaded and destroyed the roof 
of the skull; and (iv) it remained locally over a period 
of 7 years. We could not find any other case with such 
a locally aggressive behaviour but without the further 
metastatic spread. The occurrence of a relapse five 
years after the first diagnosis is quite characteristic. 
Most LMM relapse between 3 to 5 years [16]. 
Treatment of LMM consists of surgery with 
wide excision, staged excision or Mohs surgery. 
Nevertheless, a higher recurrence rate has been 
reported for LMM, depending on histopathological 
methods for tumour margin examination, safety 
margins, and length of follow-up. With an average 
safety margin of 5 mm, only 56% of tumours could be 
cleared, while a safety margin of 15 mm achieved a 
97% complete clearance rate (17Felton et al. 2016). 
Therefore, a 5-mm safety margin is inadequate for 
LMM. However, 15 mm is not always possible like in 
the face. A better choice is Mohs surgery or staged 
excision [17]. With staged excision, the recurrence 
rate within a mean of 11.5 years was 5.9 % [18]. By 
staged excision or slow Mohs technique, formalin-
fixed tissue specimen are used that offer a better 
quality of tissue sections than frozen sections do. In a 
retrospective study comparing serial excision (slow 
Mohs) with Mohs micrographic technique on frozen 
sections, the recurrence rate was 7.3% and 33.0%, 
respectively [19]. On average, recurrence rates of 8% 
to 20% have been reported with standard surgery 
compared to 4% to 5 % by Mohs surgery [20]. 
Topical treatment with ingenol mebutate, 
imiquimod or cryotherapy is not recommended due to 
the ill-defined tumour borders and the microscopic 
growth pattern along the hair follicles deep 
downwards. Also, the progression of lentigo maligna 
into LMM has been reported after topical treatment 
[21]. Relapse rate after topical therapy or cryosurgery 
ranges from 20% to 100% after five years [20]. 
For patients who refuse surgery or could not 
be operated for medical reasons, a radiotherapy is a 
therapeutic option. An 88% complete clearance rate 
has been reported for lentigo maligna and early LMM 
using 100 to 160 Gy fractioned Grenz rays [22]. 
Debulking surgery is an established method 
to reduce tumour load in advanced melanoma [23]. In 
metastatic melanoma, debulking surgery may be 
necessary in emergency situations in case of heavily 
bleeding or obstructing tumour growth for instance 
[24]. 
Skull roof invasion by melanoma is very rare. 
It can occasionally be seen in patients with squamous 
cell carcinoma of the skin, basal cell carcinoma and 
rare neoplastic adnexal tumours of skin [25-30]. 
Research on PubMed with “lentigo maligna 
melanoma” and “skull roof invasion” provided not a 
single hit. 
The management of skull invasion warrants 
interdisciplinary cooperation. Therefore, the patient 
had been presented to the interdisciplinary tumour 
board. 
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